Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.

  title={Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.},
  author={Caroline R. Baumal and Roger A. Goldberg and Jordana G Fein},
  journal={Ophthalmic surgery, lasers & imaging retina},
  volume={46 4},
BACKGROUND AND OBJECTIVE To evaluate initial treatment of high-risk retinopathy of prematurity (ROP) with low-dose intravitreal ranibizumab. PATIENTS AND METHODS Case series of premature infants with high-risk pre-threshold or threshold posterior ROP receiving primary therapy with 0.2 mg ranibizumab. Pre-treatment and post-injection examination, RetCam (Clarity Medical Systems, Pleasanton, CA) images, fluorescein angiography, resolution of ROP and plus disease, and stability of examinations… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS